 |
Email the Society |
 |
Donations |
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
|
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | |||
|
Relationship between gene variant and Fibromyalgia
Wednesday 23 March 2011
U Texas "confirms a relationship" between gene variant & fibromyalgia; may explain differing subgroup responses to meds
Abstract:
Genetic Polymorphisms of the Beta 2-Adrenergic Receptor Relate to Guanosine Protein-coupled Stimulator Receptor Dysfunction in Fibromyalgia Syndrome – Source: Journal of Rheumatology, Mar 15, 2011
by Yangming Xiao, Weijing He, I Jon Russell
Objective: To determine the genotype frequencies of Beta (2)-adrenergic receptor (Beta (2)AR) gene polymorphisms (Gly16Arg, Glu27Gln) in patients with fibromyalgia syndrome (FM) by comparison with unrelated healthy controls.
We sought any clinical association with these polymorphisms and determined whether the polymorphisms would associate with a biologic guanosine protein-coupled stimulator receptor (Gs) dysfunction in FM.
Methods: Study subjects included 97 clinically characterized patients with FM and 59 controls. The Beta (2)AR polymorphisms at codons 16 and 27 were determined using polymerase chain reaction-restriction fragment length polymorphism. The Gs functions of peripheral blood mononuclear cells (PBMC) were tested using isoproterenol (ISO) as the adrenergic Gs ligand and measuring intracellular cyclic adenosine monophosphate (cAMP) levels.
Results:
- The frequency of the Beta (2)AR gene polymorphism Gly16Arg in FM (43.5%) was significantly lower than in controls (63.2%), suggesting that this genotype might have some effect on the risk of developing FM.
- The only clinical association in FM was with sleep dysfunction.
- Patients with FM who carried the Beta (2)AR polymorphism Arg16Arg also exhibited significantly lower PBMC basal cAMP levels (p < 0.05) and lower ISO-stimulated cAMP levels (p < 0.05) than FM carrying Gly16Gly or Gly16Arg.
Conclusion:
- This confirms a relationship between Beta (2)AR polymorphism and FM.
- It is the first study to demonstrate Beta (2)AR polymorphism-related differences in intracellular cAMP responses of FM PBMC after Beta (2)AR stimulation in vitro.
- These findings may explain some of the differences in responsiveness of FM subgroups to the adrenergic agonist medications currently approved for FM treatment.
Source: Journal of Rheumatology, Mar 15, 2011. PMID: 21406495, by Xiao Y, He W, Russell IJ. Divisions of Clinical Immunology and Infectious Diseases, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas, USA. [E-mail: russell@uthscsa.edu]
The above, with comments, originally appeared here.
|
More Fibromyalgia News |
blog comments powered by Disqus
Previous Page |
